iECURE Appoints Brian Di Donato to Board of Directors
September 15, 2021
PHILADELPHIA—(BUSINESS WIRE)—iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced it has appointed Brian Di Donato, MBA to its Board of Directors. Mr. Di Donato has more than 20 years of financial and leadership experience and currently serves as chief financial officer and head of strategy at Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies.
“Brian brings significant financial and capital market expertise to our Board, which will be helpful as we build iECURE and continue development of our pipeline of gene insertion therapies,” said Joseph Truitt, chief executive officer of iECURE. “We look forward to his guidance and support.”
Prior to joining Immunocore, Mr. Di Donato served as senior vice president and chief financial officer at Achillion Pharmaceuticals and held leadership roles in several financial services companies, including Morgan Stanley and UBS Securities.
“iECURE has an exceptional opportunity to realize Jim Wilson’s vision of curing some of the most devastating metabolic disorders by inserting copies of healthy genes into patients’ genomes,” said Mr. Di Donato, “I’m looking forward to help steer the company as it embarks on this lofty mission.”
Mr. Di Donato holds an MBA from New York University’s Stern School of Business and B.S. degrees in biology from Penn State University and mechanical engineering from Villanova University. Mr. Di Donato also served in the U.S. Navy as an aerospace engineering officer.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach. For more information, visit www.iecure.com and follow on LinkedIn.